Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance
Portfolio Pulse from Vandana Singh
AngioDynamics Inc (NASDAQ: ANGO) reported a smaller-than-expected adjusted EPS loss for Q4 2024 and beat sales estimates. The company announced a $15 million stock repurchase program and provided an optimistic outlook for fiscal year 2025, expecting net sales to grow by 4.2%-6.4% year over year. ANGO shares rose 25.6% following the news.
July 16, 2024 | 5:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AngioDynamics reported a smaller-than-expected adjusted EPS loss and beat sales estimates for Q4 2024. The company announced a $15 million stock repurchase program and provided an optimistic outlook for fiscal year 2025, expecting net sales to grow by 4.2%-6.4% year over year. Shares rose 25.6% following the news.
The positive earnings report, stock repurchase program, and optimistic guidance for FY 2025 are likely to boost investor confidence and drive the stock price up in the short term. The significant rise in share price following the news indicates strong market approval.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100